Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Healthcare

Daily deal net: June 17, 2019
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Kiadis calls up Cytosen
University of Central Florida's Cytosen has been acquired in an all-stock deal by Kiadis Pharma, in a transaction potentially worth up to $70m.
Corporates align with Purigen in series B round
Roche participated in the Agilent Technologies-led round, which will fund the launch of Stanford spinout Purigen's isotachophoresis-based DNA and RNA sample preparation platform.
Exscientia extracts GT Apeiron partnership
Dundee-founded drug discovery company Exscientia has entered into a collaboration agreement with GT Apeiron, whose parent GT Healthcare invested in the spinout’s series B round.
Merck tackles $773m Tilos acquisition
Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics, based on research at Harvard Medical School and Brigham & Women’s Hospital.
Artizan masters series A
Artizan, a Yale University spinout focused on intestinal microbiota targets potentially responsible for inflammatory bowel disease, has been backed by investors including Brii Biosciences, bringing its total funding to $12m.
Third Rock counts $770m for fifth fund
Third Rock’s fifth vehicle will bid to form and invest in more promising biotech ventures to follow the likes of multiple spinouts, such as Johns Hopkins' Thrive Earlier Detection.
Buffalo ignites Innovation Hub
University of Buffalo and Buffalo Niagara Medical Science have cut the ribbon on a new $32m innovation program aimed at commercialising local medical research.

Other News

Daily deal net: June 6, 2019
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Strand lines up $6m
Strand Therapeutics has raised seed funding to develop an mRNA engineering platform based on MIT research as it looks to assemble a pipeline of oncological drug candidates.
Bio-Techne sweeps up B-Mogen
Bio-Techne has bought University of Minnesota-founded genome editing platform operator B-Mogen Biotechnologies to solidify a business relationship that dates to 2016.
Columbia reaches Hudson Heights with $130m
Deerfield Management and Columbia University have launched a $130m commercialisation fund, Hudson Heights Innovation, to support the university's early-stage biomedical research.
OncoMyx hits $25m
OncoMyx Therapeutics was co-founded by ASU's Grant McFadden and will use the series A funding to advance the development of its lead asset aimed at several indications of cancer.
Daily deal net: June 5, 2019
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Editor's Picks

When worlds collide – CVC interest in spinouts
Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg

Login